- Home
- TS vs DGX Comparison
TS vs DGX Comparison
Compare TS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TS
- DGX
- Stock Information
- Founded
- TS 2001
- DGX 1967
- Country
- TS Luxembourg
- DGX United States
- Employees
- TS N/A
- DGX N/A
- Industry
- TS Steel/Iron Ore
- DGX Medical Specialities
- Sector
- TS Industrials
- DGX Health Care
- Exchange
- TS Nasdaq
- DGX Nasdaq
- Market Cap
- TS 19.0B
- DGX 19.8B
- IPO Year
- TS N/A
- DGX 1996
- Fundamental
- Price
- TS $36.47
- DGX $179.79
- Analyst Decision
- TS Buy
- DGX Buy
- Analyst Count
- TS 6
- DGX 14
- Target Price
- TS $43.33
- DGX $185.07
- AVG Volume (30 Days)
- TS 1.5M
- DGX 894.9K
- Earning Date
- TS 07-30-2025
- DGX 07-22-2025
- Dividend Yield
- TS 6.03%
- DGX 1.78%
- EPS Growth
- TS N/A
- DGX 6.41
- EPS
- TS 1.63
- DGX 7.91
- Revenue
- TS $12,004,602,000.00
- DGX $10,158,000,000.00
- Revenue This Year
- TS N/A
- DGX $10.38
- Revenue Next Year
- TS $0.04
- DGX $4.03
- P/E Ratio
- TS $10.74
- DGX $22.73
- Revenue Growth
- TS N/A
- DGX 9.38
- 52 Week Low
- TS $27.24
- DGX $135.47
- 52 Week High
- TS $40.87
- DGX $182.38
- Technical
- Relative Strength Index (RSI)
- TS 63.75
- DGX 59.71
- Support Level
- TS $35.78
- DGX $172.48
- Resistance Level
- TS $36.90
- DGX $182.38
- Average True Range (ATR)
- TS 0.61
- DGX 2.83
- MACD
- TS 0.21
- DGX 0.56
- Stochastic Oscillator
- TS 88.15
- DGX 77.14
About TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.